Differences in functional activity and antigen expression of granulocytes primed in vivo with filgrastim, lenograstim, or pegfilgrastim.
BACKGROUND
Granulocyte-colony-stimulating factor (G-CSF) is known to affect functional activity and antigen expression of neutrophil granulocytes. Beside nonglycosylated filgrastim and glycosylated lenograstim, pegylated filgrastim (pegfilgrastim) has recently been introduced for single administration into clinical use.


METHODS
Here, granulocytes from 27 patients with nonmyeloid malignancies were compared functionally (migration, reactive oxygen species production, and G-CSF serum levels) and phenotypically (cell surface antigen expression) before and after G-CSF administration.


RESULTS
After exposure to G-CSF, chemotaxis was reduced significantly in the filgrastim group. Immunophenotypically, in vivo G-CSF-primed granulocytes were more mature in the lenograstim than in the filgrastim and to lesser extent in the pegfilgrastim groups as shown by the expression profile for CD11b, CD14, and CD16. Of note, G-CSF serum levels were similar among the groups.


CONCLUSIONS
Our data suggest that granulocytes exposed to glycosylated G-CSF in vivo seem to resemble more closely their steady-state phenotype than after treatment with nonglycosylated and to lesser extent pegylated G-CSF.
Ribeiro
Daniel
D
Department of Internal Medicine V, University of Heidelberg, German Cancer Research Center, Heidelberg, Germany.
Veldwijk
Marlon R
MR
Benner
Axel
A
Laufs
Stephanie
S
Wenz
Frederik
F
Ho
Anthony D
AD
Fruehauf
Stefan
S
D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000097:blood; D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000096:biosynthesis*; D002633:Chemotaxis / Q000187:drug effects*; D005260:Female; D000069585:Filgrastim; D005786:Gene Expression Regulation / Q000187:drug effects*; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage* / Q000097:blood; D006801:Humans; D000078224:Lenograstim; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000473:pathology; D009504:Neutrophils / Q000378:metabolism* / Q000473:pathology; D011092:Polyethylene Glycols; D017382:Reactive Oxygen Species / Q000378:metabolism; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000097:blood
D000276:Adjuvants, Immunologic; D015703:Antigens, CD; D017382:Reactive Oxygen Species; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; C455861:pegfilgrastim; D011092:Polyethylene Glycols; D000078224:Lenograstim; D000069585:Filgrastim